“An Exploitable Mutation: Defect might make some lung cancers treatable” (SN: 9/11/04, p. 164: An Exploitable Mutation: Defect might make some lung cancers treatable) may have missed a “magic bullet” that would be effective against many forms of cancer. The researchers concentrate on a drug that blocks a mutated form of the epidermal growth factor (EGF) receptor, which may benefit 5 percent of lung cancer patients.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.